Related Experiment Video

Updated: Aug 21, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

[Imatinib--a new perspective in the treatment of tumors]

P Klener1, H Klamová

  • 1I. interní klinika 1. LF UK a VFN a UHKT, Praha. pavel.klener@ruk.cuni.cz

Casopis Lekaru Ceskych
|November 10, 2004
PubMed

Insights

Imatinib effectively targets specific tyrosine kinases, revolutionizing treatment for chronic myelocytic leukemia and gastrointestinal stromal tumors. This targeted therapy also shows promise for other malignancies and hypereosinophilic syndrome.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Signal transduction pathways are crucial in cancer development.
  • Targeted therapies offer novel anticancer strategies.
  • Imatinib (Glivec) is a key tyrosine kinase inhibitor.

Purpose:

  • To review current therapeutic experiences with imatinib.
  • To highlight imatinib's mechanisms of action and clinical applications.
  • To discuss potential combination therapies involving imatinib.

Summary:

  • Imatinib inhibits bcr-abl tyrosine kinase, establishing it as standard therapy for chronic myelocytic leukemia.
  • Inhibition of c-kit receptor by imatinib is effective in treating gastrointestinal stromal tumors.
  • Imatinib targets platelet-derived growth factor receptor (PDGFR) kinase, relevant in various malignancies like dermatofibrosarcoma protuberans and FIPILI-PFGFRA-driven hypereosinophilic syndrome.

Impact:

  • Imatinib has transformed the treatment landscape for specific leukemias and tumors.
  • Targeted inhibition of signal transduction pathways represents a significant advancement in cancer therapy.
  • Further research into imatinib combinations may enhance treatment efficacy.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...